IP Library Granted Patent US 11,883,502
Granted Patent B2
US 11,883,502 · App. 17/544,239 · Granted Jan 30, 2024

Methods for production of capsular polysaccharide protein conjugates from

Inventors: Michael Albert Winters (Doylestown, PA); John E. MacNair (Lansdale, PA)
Assignee: Merck Sharp & Dohme LLC
A61K47/646A61K39/092A61K47/36G01N33/56944A61K2039/6037G01N2333/315
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,883,502
App. No.
17/544,239
Granted
Jan 30, 2024
Kind
B2
Abstract

The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.

Claims (11)

1. A method for the production of a stable Streptococcus pneumoniae serotype 19F polysaccharide-CRM197 carrier protein conjugate, wherein the Streptococcus pneumoniae serotype 19F polysaccharide-CRM197 carrier protein conjugate comprises Streptococcus pneumoniae serotype 19F capsular polysaccharide covalently linked to a CRM197 carrier protein, the method comprising the steps of:

a) performing a conjugation reaction wherein Streptococcus pneumoniae serotype 19F polysaccharide is covalently linked to a CRM197 carrier protein, wherein the conjugation reaction generates a reaction mixture comprising Streptococcus pneumoniae serotype 19F polysaccharide-CRM197 carrier protein conjugates and free Streptococcus pneumoniae serotype 19F polysaccharides;

b) incubating said reaction mixture for 5-7 days at a temperature of 20-25° C. in a buffer at a pH of 6.5-7.5; and

c) performing size separation under conditions that allow removal of the free Streptococcus pneumoniae serotype 19F polysaccharides.

2. The method of claim 1 , wherein said size separation uses a nominal molecular weight cut off membrane of from 100 to 500 kDa whereby the Streptococcus pneumoniae serotype 19F polysaccharide-CRM197 carrier protein conjugate is retained.

3. The method of claim 1 , further comprising d) collecting the Streptococcus pneumoniae serotype 19F polysaccharide-CRM197 carrier protein conjugate.

4. The method of claim 2 , wherein the retained Streptococcus pneumoniae serotype 19F polysaccharide-CRM197 carrier protein conjugate has an average molecular weight of 600 kDa or more.

5. The method of claim 4 wherein the Streptococcus pneumoniae serotype 19F polysaccharide-CRM197 carrier protein conjugate has an average molecular weight of 1000 kDa or more.

6. The method of claim 1 , wherein said buffer is selected from a phosphate buffer, histidine, and TRIS.

7. The method of claim 1 , wherein said size separation is by size-exclusion chromatography, bind/elute chromatography, or wide-pore ultrafiltration.

8. The method of claim 7 , wherein said size separation is by wide-pore ultrafiltration with a membrane having a MWCO of 100 kDa to 300 kDa.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2021
From: WINTERS, MICHAEL ALBERT; MACNAIR, JOHN E.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 058325/0162 →